Editor's pick of the day: Aurobindo acquires Sandoz's dermatology and oral solids business for $900 million

India’s second-largest drugmaker Aurobindo Pharma on Thursday said it has entered into definitive agreement to acquire commercial operations and three manufacturing units from Sandoz, a Novartis generic division, in the US. The acquisition, Aurobindo’s largest ever, comprises Sandoz’s dermatology business and a portfolio of oral solid products along with commercial and manufacturing infrastructure in the US for $900 million.

This deal, and what it means for the pharma sector in general and to Aurobindo in specific, constitutes the crux of our Pick of the Day.